性感染症検査の世界市場（2019年～2029年）：規模、シェア、動向分析、機会、予測 - 疾患別、場所別、デバイス別、地域別

世界の性感染症検査の市場規模は、2022年に914億米ドルとなり、2023年から2029年の予測期間中に6.2%のCAGRで成長し、2029年には1,355億米ドルになると予測されています。市場を牽引する主な要因には、STDの有病率と発生率の増加、国家スクリーニングプログラムの確立の増加、STD検査の償還に対する支援の世界的な増加などが挙げられます。しかし、患者がSTD専門クリニックを訪れることに関連する社会的スティグマと、遠隔地でSTDに感染した患者の強力な保護は、分析期間中に市場の成長を妨げると予想されています。

当レポートでは、世界の性感染症検査市場について調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、セグメント別の市場分析、競合情勢、COVID-19の影響、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の性感染症検査市場：洞察

• 業界バリューチェーン分析
• DROC分析
  • 成長促進要因
    • 世界的なSTDの高い有病率と発生率の上昇
    • 国家スクリーニングプログラムの実施
    • STD検査の償還に対する支援
  • 抑制要因
    • STD専門クリニックを訪れる患者に関連する社会的スティグマ
    • 遠隔地でSTDに感染した患者への強力な保護
  • 機会
    • 政府診療所への訪問数の減少
    • 世界中の全国的なスクリーニングプログラム
    • 新興経済における技術およびPOC検査プロバイダーのニッチな機会
  • 課題
    • 厳しい規制
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競合の激しさ

第4章 世界の性感染症検査市場：概要

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
    • クラミジア
    • 梅毒
    • 淋病
    • ハイパーシンプレックスウイルス
    • ヒト免疫不全ウイルス
    • 下疳
    • その他
  • 場所別
    • ラボ
    • ポイントオブケア（POC）
  • デバイス別
    • 実験装置
    • ポイントオブケア（POC）デバイス
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第5章 北米の性感染症検査市場

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
  • 場所別
  • デバイス別
  • 国別
    • 米国
    • カナダ

第6章 欧州の性感染症検査市場

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
  • 場所別
  • デバイス別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • その他の欧州

第7章 アジア太平洋地域の性感染症検査市場

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
  • 場所別
  • デバイス別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア・ニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • フィリピン
    • ベトナム
    • その他のアジア太平洋地域

第8章 ラテンアメリカの性感染症検査市場

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
  • 場所別
  • デバイス別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • コロンビア
    • その他のラテンアメリカ

第9章 中東・アフリカの性感染症検査市場

• 市場規模と予測（2019年～2029年）
  • 金額別
• 市場シェアと予測
  • 疾患別
  • 場所別
  • デバイス別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • その他の中東・アフリカ

第10章 競合情勢

• 主要企業とその製品の一覧
• 世界の性感染症検査企業の市場シェア分析（2022年）
• 操作パラメータ別の競合ベンチマーキング
• 主要な戦略的動向（合併、買収、パートナーシップなど）

第11章 世界の性感染症検査市場：COVID-19の影響

第12章 企業プロファイル（企業概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先、戦略的展望、SWOT分析）

• Abbott Laboratories
• BioMerieux, Inc.
• Becton Dickinson Company
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• Diasorin Molecular LLC
• Roche Holding AG
• Orasure Technologies, Inc.,
• Thermo Fisher Scientific Inc.
• AccuBioTech Co. Ltd.
• AdvaCare Pharma
• BIOGENIX Inc. Pvt. Ltd.
• CTK Biotech Inc.
• Everlywell Inc.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Merck and Co. Inc.
• その他の有力企業

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Sexually Transmitted Disease Testing Market Size Expands to Cross USD 135.5 Billion by 2029.

Global sexually transmitted disease (STD) testing market is flourishing because of an increasing prevalence and rising incidences of STDs, growing establishment of national screening programs, and rising support for STD testing reimbursements across the globe.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global sexually transmitted disease (STD) testing market size at USD 91.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global sexually transmitted disease testing market size to grow at a steady CAGR of 6.2% reaching a value of USD 135.5 billion by 2029. Major factors for the expansion of global sexually transmitted disease testing market include increasing public awareness and patient education, global rise in the incidence of sexually transmitted illnesses, increasing patient awareness through education campaigns, and a surge in government activities. The prevalence and incidence of sexually transmitted illnesses have increased significantly during the previous decade. As the frequency of sexually transmitted illnesses increases, countries worldwide are focused on the deployment of national screening programs to expand the coverage of sexually transmitted disease diagnosis. Also, the payment regulations for services related to sexually transmitted diseases have been favorable. Technology advancements and developments in the diagnosis of STDs are also projected to boost market expansion. Increased national screening program implementation to increase sexually transmitted disease diagnosis coverage will also boost the demand for STDs testing. These reasons are considerably driving the growth of the global sexually transmitted diseases testing market. However, social stigma associated with patients visiting specialized STD clinics and huge protection of patients infected with STDs in remotes areas are anticipated to hinder the market growth during the period in analysis.

Global Sexually Transmitted Disease Testing Market - Overview

Sexual health testing is a collection of diverse tests and procedures used to diagnose and detect sexually transmitted illnesses, such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and others. For sexual health testing, four major types of testing are employed, including Culture/Isolation of Organisms, Molecular Test, Immunology Assay, and others. HIV can be diagnosed using one of three HIV tests: antibody testing, antigen/antibody tests, and nucleic acid tests (NAT). STD prevalence and incidence have risen considerably in the recent decade. As the prevalence of sexually transmitted illnesses rises, nations around the world are focusing on developing nationwide screening programs to increase the adoption of sexually transmitted disease diagnostics coverage. Reimbursement regulations for diagnostic services for sexually transmitted diseases have been useful. These factors are significantly contributing to the growth of the global sexually transmitted diseases diagnostics market.

Impact of COVID-19 on Global Sexually Transmitted Disease Testing Market

COVID-19 adversely affected the STD (sexually transmitted disease) testing market. Due to disruptions in healthcare and STD testing facilities, the CDC (Centers for Disease Control and Prevention) observed a decline in STD testing during the early months of COVID-19. Few members may have unwittingly disseminated the virus due to inadequate testing and diagnosis. As a result, even though the transmission of STDs rose during the pandemic, the market value declined due to the decrease in testing. STD testing surged once the lockdown and travel ban were lifted, and the market is projected to boost the expansion of market growth.

Global Sexually Transmitted Disease Testing Market - By Location

Based on location, global sexually transmitted disease testing market is bifurcated in Laboratory and Point of Care (PoC). In 2022, the laboratory testing segment had a higher market share, but PoC testing is expected to rise at a faster rate in the years ahead. Laboratory testing includes commercial/private labs and public health labs. Laboratory testing is a time-consuming but more exact procedure that involves commercial/private labs as well as public health labs. Likewise, the PoC segment includes testing kits, is faster, the results may be less exact. However, bedside testing or mobile testing that allows for rapid healthcare provision for patients is capturing market share. There has been a major transition from traditional laboratory tests to rapid and easy point of care tests, due to the benefits provided by point of care testing equipment.

Competitive Landscape:

Major players operating in global sexually transmitted disease testing market include: Abbott Laboratories, BioMerieux, Inc., Becton Dickinson Company, Danaher Corporation, Bio-Rad Laboratories, Inc., Hologic, Inc., Diasorin Molecular LLC, Roche Holding AG, Orasure Technologies, Inc., Thermo Fisher Scientific Inc., AccuBioTech Co. Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt. Ltd., CTK Biotech Inc., Everlywell Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, and Merck and Co. Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Sexually Transmitted Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Sexually Transmitted Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Sexually Transmitted Disease Testing Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. High Prevalence & Rise in Incidences of STD across the Globe
    • 3.2.1.2. Implementation of National Screening Programs
    • 3.2.1.3. Supporting Reimbursement of STDs Testing
  • 3.2.2. Restraints
    • 3.2.2.1. Social Stigma Associated with Patients Visiting Specialized STD Clinics
    • 3.2.2.2. Huge Protection of Patients Infected with STDs in Remotes Areas
  • 3.2.3. Opportunities
    • 3.2.3.1. Decrease In Number of Visits to Government Clinics
    • 3.2.3.2. National Screening Programs Across the Globe
    • 3.2.3.3. Niche Opportunities for Technology and POC Test Providers in an Emerging Economy
  • 3.2.4. Challenges
    • 3.2.4.1. Stringent Regulations
• 3.3. Technology Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Sexually Transmitted Disease Testing Market Overview

• 4.1. Market Size & Forecast by Value, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease
    • 4.2.1.1. Chlamydia
    • 4.2.1.2. Syphilis
    • 4.2.1.3. Gonorrhoea
    • 4.2.1.4. Hyper Simplex Virus
    • 4.2.1.5. Human Immunodeficiency Virus
    • 4.2.1.6. Chancroid
    • 4.2.1.7. Others
  • 4.2.2. By Location
    • 4.2.2.1. Laboratory
    • 4.2.2.1.1. Commercial/Private Labs
    • 4.2.2.1.2. Public Health Labs
    • 4.2.2.2. Point of Care (POC)
  • 4.2.3. By Device
    • 4.2.3.1. Laboratory Devices
    • 4.2.3.1.1. Thermal Cyclers PCR
    • 4.2.3.1.2. Lateral Flow Readers- Immune Chromatographic Arrays
    • 4.2.3.1.3. Flow Cytometers
    • 4.2.3.1.4. Differential Light Scattering Machines
    • 4.2.3.1.5. Absorbance Micro Plate Reader- Enzyme- Linked Immunosorbent Assay (ELISA)
    • 4.2.3.1.6. Others
    • 4.2.3.2. Point of Care (POC) Devices
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific
    • 4.2.4.4. Latin America
    • 4.2.4.5. Middle East and Africa

5. North America Sexually Transmitted Disease Testing Market

• 5.1. Market Size & Forecast by Value, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease
  • 5.2.2. By Location
  • 5.2.3. By Device
  • 5.2.4. By Country
    • 5.2.4.1. US
    • 5.2.4.1.1. By Disease
    • 5.2.4.1.2. By Location
    • 5.2.4.1.3. By Device
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Disease
    • 5.2.4.2.2. By Location
    • 5.2.4.2.3. By Device

6. Europe Sexually Transmitted Disease Testing Market

• 6.1. Market Size & Forecast by Value, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Location
  • 6.2.3. By Device
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Disease
    • 6.2.4.1.2. By Location
    • 6.2.4.1.3. By Device
    • 6.2.4.2. UK
    • 6.2.4.2.1. By Disease
    • 6.2.4.2.2. By Location
    • 6.2.4.2.3. By Device
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Disease
    • 6.2.4.3.2. By Location
    • 6.2.4.3.3. By Device
    • 6.2.4.4. France
    • 6.2.4.4.1. By Disease
    • 6.2.4.4.2. By Location
    • 6.2.4.4.3. By Device
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Disease
    • 6.2.4.5.2. By Location
    • 6.2.4.5.3. By Device
    • 6.2.4.6. The Netherlands
    • 6.2.4.6.1. By Disease
    • 6.2.4.6.2. By Location
    • 6.2.4.6.3. By Device
    • 6.2.4.7. Rest of Europe
    • 6.2.4.7.1. By Disease
    • 6.2.4.7.2. By Location
    • 6.2.4.7.3. By Device

7. Asia-Pacific Sexually Transmitted Disease Testing Market

• 7.1. Market Size & Forecast by Value, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Location
  • 7.2.3. By Device
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Disease
    • 7.2.4.1.2. By Location
    • 7.2.4.1.3. By Device
    • 7.2.4.2. India
    • 7.2.4.2.1. By Disease
    • 7.2.4.2.2. By Location
    • 7.2.4.2.3. By Device
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Disease
    • 7.2.4.3.2. By Location
    • 7.2.4.3.3. By Device
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Disease
    • 7.2.4.4.2. By Location
    • 7.2.4.4.3. By Device
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Disease
    • 7.2.4.5.2. By Location
    • 7.2.4.5.3. By Device
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Disease
    • 7.2.4.6.2. By Location
    • 7.2.4.6.3. By Device
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Disease
    • 7.2.4.7.2. By Location
    • 7.2.4.7.3. By Device
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Disease
    • 7.2.4.8.2. By Location
    • 7.2.4.8.3. By Device
    • 7.2.4.9. Philippines
    • 7.2.4.9.1. By Disease
    • 7.2.4.9.2. By Location
    • 7.2.4.9.3. By Device
    • 7.2.4.10. Vietnam
    • 7.2.4.10.1. By Disease
    • 7.2.4.10.2. By Location
    • 7.2.4.10.3. By Device
    • 7.2.4.11. Rest of APAC
    • 7.2.4.11.1. By Disease
    • 7.2.4.11.2. By Location
    • 7.2.4.11.3. By Device

8. Latin America Sexually Transmitted Disease Testing Market

• 8.1. Market Size & Forecast by Value, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Location
  • 8.2.3. By Device
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Disease
    • 8.2.4.1.2. By Location
    • 8.2.4.1.3. By Device
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Disease
    • 8.2.4.2.2. By Location
    • 8.2.4.2.3. By Device
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Disease
    • 8.2.4.3.2. By Location
    • 8.2.4.3.3. By Device
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Disease
    • 8.2.4.4.2. By Location
    • 8.2.4.4.3. By Device
    • 8.2.4.5. Colombia
    • 8.2.4.5.1. By Disease
    • 8.2.4.5.2. By Location
    • 8.2.4.5.3. By Device
    • 8.2.4.6. Rest of LATAM
    • 8.2.4.6.1. By Disease
    • 8.2.4.6.2. By Location
    • 8.2.4.6.3. By Device

9. Middle East & Africa Sexually Transmitted Disease Testing Market

• 9.1. Market Size & Forecast by Value, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Location
  • 9.2.3. By Device
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Disease
    • 9.2.4.1.2. By Location
    • 9.2.4.1.3. By Device
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Disease
    • 9.2.4.2.2. By Location
    • 9.2.4.2.3. By Device
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Disease
    • 9.2.4.3.2. By Location
    • 9.2.4.3.3. By Device
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Disease
    • 9.2.4.4.2. By Location
    • 9.2.4.4.3. By Device
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Disease
    • 9.2.4.5.2. By Location
    • 9.2.4.5.3. By Device
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Disease
    • 9.2.4.6.2. By Location
    • 9.2.4.6.3. By Device
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Disease
    • 9.2.4.7.2. By Location
    • 9.2.4.7.3. By Device
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Disease
    • 9.2.4.8.2. By Location
    • 9.2.4.8.3. By Device

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Sexually Transmitted Disease Testing Company Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Sexually Transmitted Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

• 12.1. Abbott Laboratories
• 12.2. BioMerieux, Inc.
• 12.3. Becton Dickinson Company
• 12.4. Danaher Corporation
• 12.5. Bio-Rad Laboratories, Inc.
• 12.6. Hologic, Inc.
• 12.7. Diasorin Molecular LLC
• 12.8. Roche Holding AG
• 12.9. Orasure Technologies, Inc.,
• 12.10. Thermo Fisher Scientific Inc.
• 12.11. AccuBioTech Co. Ltd.
• 12.12. AdvaCare Pharma
• 12.13. BIOGENIX Inc. Pvt. Ltd.
• 12.14. CTK Biotech Inc.
• 12.15. Everlywell Inc.
• 12.16. F. Hoffmann La Roche Ltd.
• 12.17. Gilead Sciences Inc.
• 12.18. GlaxoSmithKline Plc
• 12.19. Merck and Co. Inc.
• 12.20. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumption & Limitation